Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Oral TXA for Hip Fracture Blood Loss
NCT05518279Phase 3Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Sep 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hemorrhage comparing Tranexamic Acid with Placebo (2 arms). Primary endpoints: Blood transfusion rate at 7 days and Hemoglobin Level at 7 days. Planned start Sep 2019; status: withdrawn.
02
Drugs
tranexamic acid
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT05518279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518279.